GETINGE Research and Development Expenses 2016-2024 | GNGBY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GETINGE research and development expenses from 2016 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

GETINGE Research and Development Expenses 2016-2024 | GNGBY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GETINGE research and development expenses from 2016 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$93.4B
Cencora (COR)	$48.3B
DiDi Global (DIDIY)	$22.2B
Natera (NTRA)	$22.1B
ICON (ICLR)	$17.7B
Viatris (VTRS)	$16B
Avantor (AVTR)	$14.1B
Revvity (RVTY)	$13.6B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.2B
BioMerieux (BMXMF)	$11.9B
Medpace Holdings (MEDP)	$10.5B
Charles River Laboratories (CRL)	$10B
HealthEquity (HQY)	$9.1B
Doximity (DOCS)	$9B
Sonic Healthcare (SKHHY)	$8.9B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Organon (OGN)	$3.9B
Sotera Health (SHC)	$3.6B
BrightSpring Health Services (BTSG)	$3.3B
Surgery Partners (SGRY)	$2.9B
Concentras Parent (CON)	$2.8B
PACS (PACS)	$2.5B
Alignment Healthcare (ALHC)	$2.3B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.2B
GeneDx Holdings (WGS)	$2.2B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.9B